Benjamin Djulbegovic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7502117/publications.pdf

Version: 2024-02-01

397 papers	35,096 citations	14655 66 h-index	3732 179 g-index
426 all docs	426 docs citations	426 times ranked	37988 citing authors

#	Article	IF	Citations
1	Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology, 2005, 5, 13.	3.1	6,548
2	GRADE guidelines: 4. Rating the quality of evidenceâ€"study limitations (risk of bias). Journal of Clinical Epidemiology, 2011, 64, 407-415.	5.0	2,130
3	Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ: British Medical Journal, 2003, 326, 1167-1170.	2.3	1,733
4	GRADE guidelines: 5. Rating the quality of evidenceâ€"publication bias. Journal of Clinical Epidemiology, 2011, 64, 1277-1282.	5.0	1,355
5	How to increase value and reduce waste when research priorities are set. Lancet, The, 2014, 383, 156-165.	13.7	1,102
6	Recommendations on the Use of ¹⁸F-FDG PET in Oncology. Journal of Nuclear Medicine, 2008, 49, 480-508.	5.0	978
7	GRADE guidelines: 15. Going from evidence to recommendationâ€"determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology, 2013, 66, 726-735.	5.0	950
8	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49.	3.9	920
9	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. JAMA - Journal of the American Medical Association, 2009, 301, 2349.	7.4	758
10	Platelet Transfusion: A Clinical Practice Guideline From the AABB. Annals of Internal Medicine, 2015, 162, 205-213.	3.9	717
11	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 4867-4874.	1.6	675
12	Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA - Journal of the American Medical Association, 2008, 299, 914.	7.4	657
13	Progress in evidence-based medicine: a quarter century on. Lancet, The, 2017, 390, 415-423.	13.7	626
14	GRADE guidelines: 12. Preparing Summary of Findings tablesâ€"binary outcomes. Journal of Clinical Epidemiology, 2013, 66, 158-172.	5.0	618
15	Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, The, 2009, 373, 1532-1542.	13.7	546
16	Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects<subtitle>Systematic Review and Meta-regression Analysis</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1180.	7.4	524
17	Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients. Journal of the National Cancer Institute, 2006, 98, 708-714.	6.3	510
18	The uncertainty principle and industry-sponsored research. Lancet, The, 2000, 356, 635-638.	13.7	442

#	Article	IF	Citations
19	Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology, 2002, 20, 4083-4107.	1.6	393
20	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398.	1.4	374
21	The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts. Archives of Internal Medicine, 2000, 160, 1630.	3.8	343
22	Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 2009, 20, 520-525.	1.2	302
23	Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2008, 26, 132-149.	1.6	274
24	Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Oncology, 2005, 23, 4198-4214.	1.6	273
25	Evidenceâ€based practice guidelines for plasma transfusion. Transfusion, 2010, 50, 1227-1239.	1.6	269
26	Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients. Journal of Clinical Oncology, 2003, 21, 4615-4626.	1.6	263
27	Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ: British Medical Journal, 2004, 328, 22-24.	2.3	263
28	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2010, 341, c4543-c4543.	2.3	257
29	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92.	329.8	230
30	Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. Annals of Internal Medicine, 2019, 171, 756.	3.9	227
31	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. American Journal of Medicine, 2002, 112, 406-411.	1.5	216
32	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Biology of Blood and Marrow Transplantation, 2007, 13, 183-196.	2.0	216
33	Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 2002, 100, 2303-2320.	1.4	196
34	Epistemologic Inquiries in Evidence-Based Medicine. Cancer Control, 2009, 16, 158-168.	1.8	164
35	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004, 103, 3271-3277.	1.4	163
36	Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 628-653.	4.9	153

#	Article	IF	Citations
37	Guideline panels should not GRADE good practice statements. Journal of Clinical Epidemiology, 2015, 68, 597-600.	5.0	150
38	Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. Journal of Clinical Epidemiology, 2016, 80, 3-7.	5.0	145
39	Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy. New England Journal of Medicine, 2013, 368, 1131-1139.	27.0	140
40	Screening mammography at 40â€“49 years: regret or no regret?. Lancet, The, 2006, 368, 2035-2037.	13.7	134
41	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 3036-3043.	1.6	132
42	Platelet transfusion: a systematic review of the clinical evidence. Transfusion, 2015, 55, 1116-1127.	1.6	131
43	Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood, 2008, 111, 25-41.	1.4	130
44	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2009, 15, 1005-1013.	2.0	116
45	Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 908-942.	4.9	112
46	Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Systematic Reviews, 2013, 2, 10.	5.3	112
47	Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. Journal of Clinical Oncology, 2020, 38, 2558-2569.	1.6	110
48	Erythropoietin or Darbepoetin for patients with cancer. , 2006, , CD003407.		106
49	Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Instituteâ€“Sponsored Cooperative Groups. Journal of Clinical Oncology, 2007, 25, 1272-1276.	1.6	101
50	Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology, The, 2003, 4, 293-304.	10.7	100
51	Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. The Cochrane Library, 2009, , CD007303.	2.8	98
52	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2009, 101, 100-106.	6.3	97
53	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. Biology of Blood and Marrow Transplantation, 2014, 20, 1677-1686.	2.0	95
54	Treatment Success in Cancer<subtitle>New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Instituteâ€“Sponsored Cooperative Oncology Groups, 1955 to 2006</subtitle>. Archives of Internal Medicine, 2008, 168, 632.	3.8	94

#	Article	IF	Citations
55	From Efficacy to Effectiveness in the Face of Uncertainty. JAMA - Journal of the American Medical Association, 2011, 305, 2005-6.	7.4	88
56	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials, 2010, 7, 312-321.	1.6	87
57	Dual processing model of medical decision-making. BMC Medical Informatics and Decision Making, 2012, 12, 94.	3.0	86
58	Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 536.	4.9	86
59	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-98.	1.4	86
60	Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library, 2022, 2022, CD003039.	2.8	85
61	GRADE Guidelines 30: the GRADE approach to assessing the certaintyÂof modeled evidenceâ€"An overview in the context of healthÂdecision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150.	5.0	81
62	Evaluation of New Treatments in Radiation Oncology. JAMA - Journal of the American Medical Association, 2005, 293, 970.	7.4	78
63	Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology, 2012, 65, 602-609.	5.0	77
64	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Advances, 2019, 3, 1197-1210.	5.2	76
65	Bisphosphonates in multiple myeloma: a network meta-analysis. The Cochrane Library, 2012, , CD003188.	2.8	74
66	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 1336-1351.	1.6	73
67	Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane Library, 2017, 2017, CD003188.	2.8	72
68	Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1415-1421.	2.0	70
69	A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making. BMC Medical Informatics and Decision Making, 2010, 10, 51.	3.0	70
70	Bisphosphonates in multiple myeloma. , 2002, , CD003188.		69
71	When to perform hepatic resection for intermediateâ€stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914.	7.3	69
72	Scientific and Ethical Issues in Equivalence Trials. JAMA - Journal of the American Medical Association, 2001, 285, 1206.	7.4	67

#	Article	IF	Citations
73	Evidence vs Consensus in Clinical Practice Guidelines. JAMA - Journal of the American Medical Association, 2019, 322, 725.	7.4	67
74	Acceptable regret in medical decision making. Medical Hypotheses, 1999, 53, 253-259.	1.5	66
75	Articulating and Responding to Uncertainties in Clinical Research. Journal of Medicine and Philosophy, 2007, 32, 79-98.	0.8	65
76	Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia, 2012, 26, 582-588.	7.2	65
77	Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genetics in Medicine, 2013, 15, 517-527.	2.4	64
78	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology, 2020, 6, 1759.	7.1	64
79	Quality and methods of developing practice guidelines. BMC Health Services Research, 2002, 2, 1.	2.2	63
80	Multiple Myeloma, Version 1.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 11-17.	4.9	63
81	World Health Organization recommendations are often strong based on low confidence in effect estimates. Journal of Clinical Epidemiology, 2014, 67, 629-634.	5.0	62
82	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 389-400.	4.9	62
83	Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research, 2012, 18, 256-262.	7.0	61
84	Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ: British Medical Journal, 2005, 331, 1295.	2.3	58
85	World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 72, 98-106.	5.0	58
86	When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach. Medical Decision Making, 2008, 28, 540-553.	2.4	57
87	Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research. Current Oncology Reports, 2001, 3, 389-395.	4.0	56
88	When Should Potentially False Research Findings Be Considered Acceptable?. PLoS Medicine, 2007, 4, e26.	8.4	55
89	Many faces of rationality: Implications of the great rationality debate for clinical decisionâ€making. Journal of Evaluation in Clinical Practice, 2017, 23, 915-922.	1.8	55
90	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	4.9	55

#	Article	IF	Citations
91	Trial unpredictability yields predictable therapy gains. Nature, 2013, 500, 395-396.	27.8	54
92	High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica, 2003, 88, 1304-15.	3.5	53
93	Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncology, The, 2002, 3, 145-153.	10.7	51
94	When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. European Journal of Clinical Investigation, 2015, 45, 485-493.	3.4	50
95	A Systematic Review and Lessons Learned from Early Lung Cancer Detection Trials Using Low-Dose Computed Tomography of the Chest. Cancer Control, 2003, 10, 306-314.	1.8	49
96	The quality of medical evidence in hematology-oncology. American Journal of Medicine, 1999, 106, 198-205.	1.5	48
97	Evidence-Based Medicine for Rare Diseases: Implications for Data Interpretation and Clinical Trial Design. Cancer Control, 2007, 14, 160-166.	1.8	48
98	The Paradox of Equipoise: The Principle that Drives and Limits Therapeutic Discoveries in Clinical Research. Cancer Control, 2009, 16, 342-347.	1.8	48
99	Trial Sequential Boundaries for Cumulative Meta-Analyses. The Stata Journal, 2013, 13, 77-91.	2.2	48
100	Rational decision making in medicine: Implications for overuse and underuse. Journal of Evaluation in Clinical Practice, 2018, 24, 655-665.	1.8	48
101	A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 70, 111-122.	5.0	47
102	Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in Medicine, 2013, 15, 14-24.	2.4	46
103	Optimism bias leads to inconclusive resultsâ€"an empirical study. Journal of Clinical Epidemiology, 2011, 64, 583-593.	5.0	45
104	The EGAPP initiative: lessons learned. Genetics in Medicine, 2014, 16, 217-224.	2.4	45
105	Systematic Review of Piperacillin-Induced Neutropenia. Drug Safety, 2007, 30, 295-306.	3.2	44
106	Randomized Trials in Oncology Stopped Early for Benefit. Journal of Clinical Oncology, 2008, 26, 18-19.	1.6	44
107	Choosing a control intervention for a randomised clinical trial. BMC Medical Research Methodology, 2003, 3, 7.	3.1	43
108	Evaluation of Serious Adverse Drug Reactions. Archives of Internal Medicine, 2007, 167, 1041.	3.8	43

#	Article	IF	Citations
109	Evidence-Based Practice Is Not Synonymous With Delivery of Uniform Health Care. JAMA - Journal of the American Medical Association, 2014, 312, 1293.	7.4	43
110	Multiple Myeloma Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 118.	4.9	43
111	Uncertainty in Clinical Medicine. , 2011, , 299-356.		42
112	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology and Oncology, 2013, 6, 2.	17.0	42
113	Value of Repeat Head Computed Tomography after Traumatic Brain Injury: Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2014, 31, 78-98.	3.4	42
114	How do physicians decide to treat: an empirical evaluation of the threshold model. BMC Medical Informatics and Decision Making, 2014, 14, 47.	3.0	42
115	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review. Biology of Blood and Marrow Transplantation, 2009, 15, 893-902.	2.0	41
116	Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy, 2013, 5, 457-466.	2.0	41
117	Evidentiary challenges to evidence-based medicine. Journal of Evaluation in Clinical Practice, 2000, 6, 99-109.	1.8	40
118	A Systematic Review of Quality of Life Associated with Standard Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 1091-1097.	1.1	40
119	Thalidomide versus bortezomib based regimens as firstâ€line therapy for patients with multiple myeloma: A systematic review. American Journal of Hematology, 2011, 86, 18-24.	4.1	39
120	Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. Journal of Clinical Epidemiology, 2015, 68, 727-732.	5.0	39
121	Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Annals of Oncology, 2000, 11, 1591-1595.	1.2	38
122	Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer, 2002, 2, 23.	2.6	38
123	WaldenstrÃ¶mâ€™s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219.	4.9	38
124	The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. The Cochrane Library, 2016, 2016, CD009624.	2.8	38
125	Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplantation, 2012, 47, 1164-1170.	2.4	37
126	Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. The Cochrane Library, 2011, , CD008818.	2.8	36

#	Article	IF	Citations
127	Transforming clinical practice guidelines and clinical pathways into fastâ€andâ€frugal decision trees to improve clinical care strategies. Journal of Evaluation in Clinical Practice, 2018, 24, 1247-1254.	1.8	36
128	The Importance of the Preservation of the Ethical Principle of Equipoise in the Design of Clinical Trials: Relative Impact of the Methodological Quality Domains on the Treatment Effect in Randomized Controlled Trials. Accountability in Research, 2003, 10, 301-315.	2.4	35
129	Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health Services Research, 2009, 9, 120.	2.2	35
130	Adherence to antiretroviral therapy in India: A systematic review and meta-analysis. Indian Journal of Community Medicine, 2013, 38, 74.	0.4	35
131	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and metaâ€analysis. British Journal of Haematology, 2013, 163, 315-325.	2.5	35
132	New treatments compared to established treatments in randomized trials. The Cochrane Library, 2012, 10, MR000024.	2.8	34
133	Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. Journal of Clinical Epidemiology, 2013, 66, 654-659.	5.0	34
134	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane Library, 2014, 2014, CD010280.	2.8	33
135	The threshold model revisited. Journal of Evaluation in Clinical Practice, 2019, 25, 186-195.	1.8	33
136	Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials. PLoS ONE, 2013, 8, e58711.	2.5	32
137	Evaluation of Physiciansâ€™ Cognitive Styles. Medical Decision Making, 2014, 34, 627-637.	2.4	32
138	Evidence to Decision framework provides a structured â€œroadmapâ€•for making GRADE guidelines recommendations. Journal of Clinical Epidemiology, 2018, 104, 103-112.	5.0	32
139	Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica, 2020, 105, 398-406.	3.5	32
140	Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. Journal of Clinical Laboratory Analysis, 1990, 4, 430-436.	2.1	29
141	Lifting the fog of uncertainty from the practice of medicine. BMJ: British Medical Journal, 2004, 329, 1419-1420.	2.3	29
142	Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica, 2010, 95, 340-342.	3.5	29
143	Optimal type I and type II error pairs when the available sample size is fixed. Journal of Clinical Epidemiology, 2013, 66, 903-910.e2.	5.0	29
144	Comparator bias: why comparisons must address genuine uncertainties. Journal of the Royal Society of Medicine, 2013, 106, 30-33.	2.0	29

#	Article	IF	Citations
145	Thinking Styles and Regret in Physicians. PLoS ONE, 2015, 10, e0134038.	2.5	29
146	Modern health care as a game theory problem. European Journal of Clinical Investigation, 2015, 45, 1-12.	3.4	29
147	Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 2009, 10, 49.	1.6	28
148	GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. Journal of Clinical Epidemiology, 2016, 75, 115-118.	5.0	28
149	Acting on Imperfect Evidence: How Much Regret Are We Ready to Accept?. Journal of Clinical Oncology, 2005, 23, 6822-6825.	1.6	27
150	Bisphosphonates in multiple myeloma. , 2010, , CD003188.		27
151	Treatment of Patients with Multiple Myeloma: An Overview of Systematic Reviews. Acta Haematologica, 2011, 125, 8-22.	1.4	27
152	Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. Seminars in Hematology, 2008, 45, 150-159.	3.4	26
153	Indirect Treatment Comparison. The Stata Journal, 2014, 14, 76-86.	2.2	26
154	A Framework to Bridge the Gaps Between Evidence-Based Medicine, Health Outcomes, and Improvement and Implementation Science. Journal of Oncology Practice, 2014, 10, 200-202.	2.5	26
155	Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open, 2017, 7, e014661.	1.9	26
156	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. Clinical Cancer Research, 2009, 15, 3850-3855.	7.0	25
157	Evidence-based medicine in times of crisis. Journal of Clinical Epidemiology, 2020, 126, 164-166.	5.0	25
158	HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome. American Journal of Hematology, 1994, 47, 189-193.	4.1	24
159	Nonmyeloablative Allogeneic Stem-Cell Transplantation for Hematologic Malignancies: A Systematic Review. Cancer Control, 2003, 10, 17-41.	1.8	24
160	Comparison of the quality of life between HIVâ€positive haemophilia patients and HIVâ€negative haemophilia patients. Haemophilia, 1996, 2, 166-172.	2.1	24
161	Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. Genetics in Medicine, 2014, 16, 338-346.	2.4	24
162	Improving the Drug Development Process. JAMA - Journal of the American Medical Association, 2014, 311, 355.	7.4	23

#	Article	IF	Citations
163	Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval. Journal of Clinical Epidemiology, 2018, 98, 24-32.	5.0	23
164	High-Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis. Cancer Control, 1998, 5, 394-405.	1.8	22
165	Uncertainty and Equipoise: At Interplay Between Epistemology, Decision Making and Ethics. American Journal of the Medical Sciences, 2011, 342, 282-289.	1.1	22
166	Rationality, practice variation and personâ€centred health policy: a threshold hypothesis. Journal of Evaluation in Clinical Practice, 2015, 21, 1121-1124.	1.8	22
167	Are systematic reviews more cost-effective than randomised trials?. Lancet, The, 2006, 367, 2057-2058.	13.7	21
168	A unifying framework for improving health care. Journal of Evaluation in Clinical Practice, 2019, 25, 358-362.	1.8	21
169	Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis. BMJ, The, 2021, 375, e066045.	6.0	21
170	Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. , 1996, 51, 168-170.		20
171	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials, 2011, 8, 591-600.	1.6	20
172	Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2000, , CD003039.		19
173	Towards theory integration: Threshold model as a link between signal detection theory, fastâ€andâ€frugal trees and evidence accumulation theory. Journal of Evaluation in Clinical Practice, 2017, 23, 49-65.	1.8	19
174	Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk. PLoS ONE, 2018, 13, e0193169.	2.5	19
175	US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials. JAMA Network Open, 2019, 2, e1911111.	5.9	19
176	The natural history of refractory idiopathic thrombocytopenic purpura. Blood, 2001, 98, 2282-2283.	1.4	18
177	Oncology treatment recommendations can be supported only by 1â€“2% of high-quality published evidence. Cancer Treatment Reviews, 2005, 31, 319-322.	7.7	18
178	Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches.Journal of Evaluation in Clinical Practice12, 248-256. Journal of Evaluation in Clinical Practice, 2006, 12, 257-259.	1.8	18
179	Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?. Genetics in Medicine, 2013, 15, 612-617.	2.4	18
180	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	7.7	18

#	Article	IF	Citations
181	Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Practice and Research in Clinical Haematology, 2005, 18, 455-466.	1.7	17
182	Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. Seminars in Hematology, 2008, 45, 167-175.	3.4	17
183	Extensions to Regret-based Decision Curve Analysis: An application to hospice referral for terminal patients. BMC Medical Informatics and Decision Making, 2011, 11, 77.	3.0	17
184	Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.. Blood, 2007, 110, 125-125.	1.4	17
185	A data-mining approach to improving Polycythemia Vera diagnosis. Computers and Industrial Engineering, 2002, 43, 765-773.	6.3	16
186	In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. British Journal of Haematology, 2006, 132, 656-658.	2.5	16
187	Implications of the Principle of Question Propagation for Comparative-Effectiveness and â€œData Miningâ€•Research. JAMA - Journal of the American Medical Association, 2011, 305, 298.	7.4	16
188	A Flexible Alternative to the Cox Proportional Hazards Model for Assessing the Prognostic Accuracy of Hospice Patient Survival. PLoS ONE, 2012, 7, e47804.	2.5	16
189	Defining Optimum Treatment of Patients With Pancreatic Adenocarcinoma Using Regret-Based Decision Curve Analysis. Annals of Surgery, 2014, 259, 1208-1214.	4.2	16
190	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	2.4	16
191	Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. Journal of Clinical Epidemiology, 2016, 70, 123-128.	5.0	16
192	Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PLoS ONE, 2015, 10, e0134800.	2.5	16
193	Occurrence of high-grade T-Cell lymphoma in a patient with philadelphia chromosome-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: Case report and review of the literature. American Journal of Hematology, 1991, 36, 63-64.	4.1	15
194	Use of re-randomized data in meta-analysis. BMC Medical Research Methodology, 2005, 5, 17.	3.1	15
195	Eliciting regret improves decision making at the end of life. European Journal of Cancer, 2016, 68, 27-37.	2.8	15
196	At What Level of Collective Equipoise Does a Randomized Clinical Trial Become Ethical for the Members of Institutional Review Board/Ethical Committees?. Acta Informatica Medica, 2013, 21, 156.	1.1	15
197	Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta Informatica Medica, 2015, 23, 196.	1.1	15
198	Equation and Nomogram for Calculation of Testing and Treatment Thresholds. Medical Decision Making, 1996, 16, 198-199.	2.4	14

#	Article	IF	Citations
199	At what degree of belief in a research hypothesis is a trial in humans justified?. Journal of Evaluation in Clinical Practice, 2002, 8, 269-276.	1.8	14
200	Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis. Cancer Treatment Reviews, 2013, 39, 340-349.	7.7	14
201	Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control, 2015, 22, 235-241.	1.8	14
202	The Second Mediterranean Seminar on Science Writing, Editing and Publishing (SWEP - 2018), Sarajevo, December 8th, 2018. Acta Informatica Medica, 2018, 26, 284.	1.1	14
203	Impact of spinal needle type on postdural puncture headache among women undergoing Cesarean section surgery under spinal anesthesia: A metaâ€•analysis. Journal of Evidence-Based Medicine, 2018, 11, 136-144.	2.4	14
204	A user guide to the American Society of Hematology clinical practice guidelines. Blood Advances, 2020, 4, 2095-2110.	5.2	14
205	Certainty of evidence and intervention's benefits and harms are key determinants of guidelinesâ€™ recommendations. Journal of Clinical Epidemiology, 2021, 136, 1-9.	5.0	14
206	Mathematical Model of Acute Myeloblastic Leukaemia: an Investigation of the Relevant Kinetic Parameters. Cell Proliferation, 1985, 18, 307-319.	5.3	13
207	What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treatment Reviews, 2006, 32, 572-576.	7.7	13
208	Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. Journal of Clinical Epidemiology, 2017, 86, 129-139.	5.0	13
209	Tolerating uncertainty about conceptual models of uncertainty in health care. Journal of Evaluation in Clinical Practice, 2019, 25, 183-185.	1.8	13
210	Precision medicine for individual patients should use population group averages and larger, not smaller, groups. European Journal of Clinical Investigation, 2019, 49, e13031.	3.4	13
211	The Sound and the Fury: Financial Conflicts of Interest in Oncology. Journal of Clinical Oncology, 2007, 25, 3567-3569.	1.6	12
212	Timing of first-line cancer treatments â€“ Early versus late â€“ A systematic review of phase III randomized trials. Cancer Treatment Reviews, 2010, 36, 621-628.	7.7	12
213	When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Medical Research Methodology, 2012, 12, 85.	3.1	12
214	Structured decision-making drives guidelines panels' recommendations â€œforâ€•but not â€œagainstâ€•health interventions. Journal of Clinical Epidemiology, 2019, 110, 23-33.	5.0	12
215	Can we trust strong recommendations based on low quality evidence?. BMJ, The, 2021, 375, n2833.	6.0	12
216	Using the Internet to Calculate Clinical Action Thresholds. Journal of Biomedical Informatics, 1999, 32, 168-185.	0.7	11

#	Article	IF	Citations
217	Is clinical research still too haphazard?. Lancet, The, 2001, 358, 1648.	13.7	11
218	Placebo-Controlled Trials. Annals of Internal Medicine, 2001, 135, 62.	3.9	11
219	Evaluation and appraisal of randomized controlled trials in myeloma. Annals of Oncology, 2001, 12, 1611-1617.	1.2	11
220	What does randomisation achieve?. Evidence-Based Medicine, 2012, 17, 1-2.	0.6	11
221	Evidenceâ€based medicine meets personâ€centred care: a collaborative perspective on the relationship. Journal of Evaluation in Clinical Practice, 2015, 21, 1047-1051.	1.8	11
222	Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations. European Journal of Cancer, 2017, 75, 159-166.	2.8	11
223	Failure to place evidence at the centre of quality improvement remains a major barrier for advances in quality improvement. Journal of Evaluation in Clinical Practice, 2019, 25, 369-372.	1.8	11
224	The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treatment Reviews, 2005, 31, 628-639.	7.7	10
225	Multiple myeloma: detecting the effects of new treatments. Lancet, The, 2008, 371, 1642-1644.	13.7	10
226	Human Judgment and Health Care Policy. Population Health Management, 2014, 17, 139-140.	1.7	10
227	Bisphosphonates for Patients Diagnosed With Multiple Myeloma. JAMA - Journal of the American Medical Association, 2018, 320, 1483.	7.4	10
228	Evaluation of the U.S. governors' decision when to issue stayâ€atâ€home orders. Journal of Evaluation in Clinical Practice, 2020, 26, 1347-1351.	1.8	10
229	Designing patient-centric applications for chronic disease management. , 2011, 2011, 3146-9.		9
230	Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials. Contemporary Clinical Trials, 2013, 34, 257-261.	1.8	9
231	A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. Blood, 2008, 112, 236-236.	1.4	9
232	Hodgkin Disease/Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 594.	4.9	9
233	Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood, 2011, 118, 3979-3979.	1.4	9
234	Comparison of Different Treatment strategies for Diffuse Large-cell Lymphomas. Medical Decision Making, 1991, 11, 1-8.	2.4	8

#	Article	IF	Citations
235	Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. British Journal of Haematology, 2007, 139, 234-242.	2.5	8
236	Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?. Leukemia Research and Treatment, 2013, 2013, 1-4.	2.0	8
237	Rough set theory based prognostic classification models for hospice referral. BMC Medical Informatics and Decision Making, 2015, 15, 98.	3.0	8
238	Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA Oncology, 2015, 1, 1301.	7.1	8
239	Activating clinical trials: a process improvement approach. Trials, 2016, 17, 106.	1.6	8
240	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265.	2.9	8
241	A few panel members dominated guideline development meeting discussions: Social network analysis. Journal of Clinical Epidemiology, 2022, 141, 1-10.	5.0	8
242	Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX Concentrate. Annals of Internal Medicine, 1991, 115, 621.	3.9	7
243	Residual mediastinal mass after treatment of Hodgkin's disease: A decision analysis. Medical Hypotheses, 1992, 38, 166-175.	1.5	7
244	Concomitant Treatment with Factor IX Concentrates and Antif ibrinolytics in Hemophilia B. Acta Haematologica, 1995, 94, 43-48.	1.4	7
245	High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone Marrow Transplantation, 2015, 50, 1069-1074.	2.4	7
246	Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account. Journal of Evaluation in Clinical Practice, 2018, 24, 65-71.	1.8	7
247	The importance of randomised vs non-randomised trials. Lancet, The, 2019, 394, 634-635.	13.7	7
248	Ethics of uncertainty. Patient Education and Counseling, 2021, 104, 2628-2634.	2.2	7
249	A new algorithm for diagnosis of anemia. Postgraduate Medicine, 1989, 85, 119-130.	2.0	6
250	High-Dose Chlorambucil and Dexamethasone for Relapsed Non-HodgkinÊ¼s Lymphomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 319-322.	1.3	6
251	The Australian 'FORM' approach to guideline development: The quest for the perfect system. BMC Medical Research Methodology, 2011, 11, 17.	3.1	6
252	Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC Medical Research Methodology, 2011, 11, 55.	3.1	6

#	Article	IF	Citations
253	From hospice to hospital: short-term follow-up study of hospice patient outcomes in a US acute care hospital surveillance system. BMJ Open, 2014, 4, e005196-e005196.	1.9	6
254	Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA Oncology, 2016, 2, 1499.	7.1	6
255	Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. Journal of Evaluation in Clinical Practice, 2017, 23, 241-250.	1.8	6
256	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. Journal of Clinical Epidemiology, 2019, 108, 1-9.	5.0	6
257	Role of Iron Supplementation to Erythropoiesis Stimulating Agents In the Management of Chemotherapy-Induced Anemia In Cancer Patients: A Systematic Review and Meta-Analysis. Blood, 2010, 116, 2055-2055.	1.4	6
258	JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS ONE, 2010, 5, e13591.	2.5	6
259	Effect of Initial Conditions on Reproducibility of Scientific Research. Acta Informatica Medica, 2014, 22, 156.	1.1	6
260	Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies. Blood, 2012, 120, 4168-4168.	1.4	6
261	Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible. Journal of Clinical Epidemiology, 2022, 145, 101-111.	5.0	6
262	Differentiated HL-60 promyelocytic leukaemia cells produce a factor inducing differentiation. Leukemia Research, 1987, 11, 259-264.	0.8	5
263	Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2009, 101, 966-967.	6.3	5
264	Evolution of Treatment Regimens in Multiple Myeloma: A Social Network Analysis. PLoS ONE, 2014, 9, e104555.	2.5	5
265	Concordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review. BMC Medical Informatics and Decision Making, 2014, 14, 57.	3.0	5
266	Monte Carlo decision curve analysis using aggregate data. European Journal of Clinical Investigation, 2017, 47, 176-183.	3.4	5
267	Hematological Malignancies and Arterial Thromboembolism. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 611-624.	0.6	5
268	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Settingâ€"Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884.	2.4	5
269	Heuristic value-based framework for lung cancer decision-making. Oncotarget, 2018, 9, 29877-29891.	1.8	5
270	High quality (certainty) evidence changes less often than lowâ€quality evidence, but the magnitude of effect size does not systematically differ between studies with low versus highâ€quality evidence. Journal of Evaluation in Clinical Practice, 2022, 28, 353-362.	1.8	5

#	Article	IF	Citations
271	Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. Journal of Clinical Epidemiology, 2022, 148, 193-195.	5.0	5
272	An Estimation of Life Expectancy: The Method Is a Message. Medical Decision Making, 1993, 13, 245-246.	2.4	4
273	Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures. American Journal of Hematology, 1995, 50, 229-230.	4.1	4
274	Letter to the Editor. Journal of Law, Medicine and Ethics, 2003, 31, 5-6.	0.9	4
275	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2004, 5, 285-285.	1.4	4
276	Rough Set Theory based prognostication of life expectancy for terminally ill patients. , 2011, 2011, 6438-41.		4
277	Patientsâ€™ values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. BMJ Open, 2014, 4, e005536.	1.9	4
278	Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies. Annals of Epidemiology, 2014, 24, 734-740.	1.9	4
279	Treatment-related harms: What was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. Journal of Clinical Epidemiology, 2014, 67, 354-356.	5.0	4
280	Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of Clinical Epidemiology, 2016, 77, 84-90.	5.0	4
281	GRADE Guidelines: 29. Rating the certainty in time-to-event outcomesâ€”Study limitations due to censoring of participants with missing data in intervention studies. Journal of Clinical Epidemiology, 2021, 129, 126-137.	5.0	4
282	Evidence, values, and masks for control of COVID-19. Journal of Clinical Epidemiology, 2021, 131, 152-157.	5.0	4
283	Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Blood, 2008, 112, 3632-3632.	1.4	4
284	A Social Network Analysis of Treatment Discoveries in Cancer. PLoS ONE, 2011, 6, e18060.	2.5	4
285	Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. Lancet Haematology,the, 2022, 9, e12-e13.	4.6	4
286	Diagnostic entropy as a function of therapeutic benefit/risk ratio. Medical Hypotheses, 1995, 45, 503-509.	1.5	3
287	Informing Patients of Uncertainty in Clinical Trialsâ€”Reply. JAMA - Journal of the American Medical Association, 2001, 285, 2713.	7.4	3
288	Erythropoietin improves quality of lifeâ€”a response. Lancet Oncology, The, 2002, 3, 527.	10.7	3

#	Article	IF	Citations
289	Clinical Equipoise and the Therapeutic Misconception. Hastings Center Report, 2003, 33, 4.	1.0	3
290	Evidence-based oncology in cancer treatment reviews. Cancer Treatment Reviews, 2003, 29, 45-50.	7.7	3
291	Evidence profiles for breast cancer: Benefit/harms data based on the totality of randomized evidence. Cancer Treatment Reviews, 2007, 33, 87-89.	7.7	3
292	Critical reflections on value in medicine. Journal of Medicine and the Person, 2013, 11, 69-72.	0.1	3
293	External validation of A Web-Based Prognostic Tool for Predicting Survival for Patients in Hospice Care. Journal of Palliative Care, 2013, 29, 140-146.	1.0	3
294	Benchmarks for detecting â€˜breakthroughsâ€™ in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation. BMJ Open, 2014, 4, e005249.	1.9	3
295	Modern health care as a game theory problem: reply. European Journal of Clinical Investigation, 2015, 45, 443-443.	3.4	3
296	Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematology,the, 2016, 3, e210-e211.	4.6	3
297	What does evidence mean? Most languages translate â€œevidenceâ€•into â€œproofâ€• Journal of Evaluation in Clinical Practice, 2017, 23, 971-973.	1.8	3
298	Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. Journal of Geriatric Oncology, 2020, 11, 1293-1308.	1.0	3
299	Some thoughts on conducting and implementing clinical practice guidelines in a pandemic. Chinese Medical Journal, 2021, 134, 910-912.	2.3	3
300	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. Blood, 2007, 110, 936-936.	1.4	3
301	Role of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review and Meta-Analysis.. Blood, 2007, 110, 2872-2872.	1.4	3
302	Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ, The, 2002, 325, 1420; author reply 1420.	6.0	3
303	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment, 2010, 121, 771-776.	2.5	2
304	Colony-Stimulating Factors for Febrile Neutropenia. New England Journal of Medicine, 2013, 369, 284-286.	27.0	2
305	When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open, 2016, 6, e011150.	1.9	2
306	Statins for Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 171, 73.	3.9	2

#	Article	IF	Citations
307	When are randomized trials unnecessary? A signal detection theory approach to approving new treatments based on nonâ€randomized studies. Journal of Evaluation in Clinical Practice, 2020, 27, 735-742.	1.8	2
308	Plasmapheresis in the Treatment of Renal Failure Associated with Multiple Myeloma.. Blood, 2006, 108, 3585-3585.	1.4	2
309	Comparative Effectiveness of Bisphoshonates In Multiple Myeloma. Blood, 2010, 116, 3028-3028.	1.4	2
310	Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients. Blood, 2015, 126, 2505-2505.	1.4	2
311	Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.. Blood, 2004, 104, 232-232.	1.4	2
312	Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.. Blood, 2005, 106, 751-751.	1.4	2
313	Clinical equipoise and the therapeutic misconception. Hastings Center Report, 2003, 33, 4; author reply 4-5.	1.0	2
314	Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. The Journal of Supportive Oncology, 2010, 8, 84-91.	2.3	2
315	Industry-sponsored research. Lancet, The, 2000, 356, 2194.	13.7	1
316	Priority-setting decisions for new cancer drugs. Lancet, The, 2002, 359, 1525.	13.7	1
317	Off-study availability of investigational treatments. Lancet, The, 2003, 361, 1302.	13.7	1
318	Evidence-based Oncology section â€“ policies and scope. Cancer Treatment Reviews, 2003, 29, 121-122.	7.7	1
319	High-quality evidence in oncology from 20th April to 11th May 2004: a summary. Cancer Treatment Reviews, 2004, 30, 665-667.	7.7	1
320	Cancer treatment reviews welcomes submission of the Cochrane Reviews. Cancer Treatment Reviews, 2006, 32, 243-244.	7.7	1
321	Efficacy Research and Unanswered Clinical Questionsâ€”Reply. JAMA - Journal of the American Medical Association, 2011, 306, 709.	7.4	1
322	Towards a classification model to identify hospice candidates in terminally ill patients. , 2012, 2012, 1278-81.		1
323	Sequence of novel agents in multiple myeloma: An instrumental variable analysis. Leukemia Research, 2013, 37, 1077-1082.	0.8	1
324	Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. , 2014, 2014, 3434-7.		1

#	Article	IF	Citations
325	The predicament of patients with suspected Ebola. The Lancet Global Health, 2017, 5, e657.	6.3	1
326	On evidence-based medicine â€“ Authors' reply. Lancet, The, 2017, 390, 2245-2246.	13.7	1
327	Research synthesis of information theory measures of uncertainty: Metaâ€analysis of entropy and mutual information of diagnostic tests. Journal of Evaluation in Clinical Practice, 2021, 27, 246-255.	1.8	1
328	The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist, 2021, 26, e1418-e1426.	3.7	1
329	Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).. Blood, 2007, 110, 5131-5131.	1.4	1
330	Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.. Blood, 2009, 114, 3858-3858.	1.4	1
331	Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.. Blood, 2010, 116, 1513-1513.	1.4	1
332	Social Network Analysis (SNA) of Research Programs In Multiple Myeloma (MM). Blood, 2011, 118, 3144-3144.	1.4	1
333	Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5142-5142.	1.4	1
334	Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. Blood, 2013, 122, 5372-5372.	1.4	1
335	When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?. Blood, 2016, 128, 4007-4007.	1.4	1
336	Talking about Treatment. Annals of Internal Medicine, 2000, 132, 94.	3.9	1
337	Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years. Annals of Internal Medicine, 2007, 147, 882.	3.9	1
338	Well informed uncertainties about the effects of treatment. BMJ: British Medical Journal, 2004, 328, 1018.2.	2.3	1
339	Are Statistically Non-Significant Findings Necessarily Negative? A Review of All Phase III Randomized Controlled Trials in Hematology Conducted by NCI Sponsored Cooperative Groups.. Blood, 2005, 106, 293-293.	1.4	1
340	Expectation Bias-the Main Culprit for Large Number of Inconclusive Randomized Controlled Trials in Hematological Malignancies. Blood, 2008, 112, 671-671.	1.4	1
341	Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. Blood, 2011, 118, 1878-1878.	1.4	1
342	Diagnostic Predictive Model for Diagnosis of Heart Failure after Hematopoietic Cell Transplantation (HCT): Comparison of Traditional Statistical with Machine Learning Modeling. Blood, 2019, 134, 5799-5799.	1.4	1

#	Article	IF	Citations
343	On Occasion of the 12th Â“Days of AMNuBiH 2021Â” and Â“SWEP 2021Â” Conferences, Sarajevo, Bosnia and Herzegovina. Acta Informatica Medica, 2021, 29, 295.	1.1	1
344	A Young Man with Lymphocytosis. Cancer Control, 1999, 6, 1-5.	1.8	0
345	Acquired anaemias and polycythaemia. Lancet, The, 2000, 356, 596.	13.7	0
346	Overlooking patient outcomes in a meta-analysis of trials of granulocyte colon-stimulating factor. American Journal of Medicine, 2002, 113, 766-768.	1.5	0
347	Evidence-based Oncology section â€“ aims and scope. Cancer Treatment Reviews, 2003, 29, 51-53.	7.7	0
348	High-quality evidence in oncology from 18th May to 15th June 2004: a summary. Cancer Treatment Reviews, 2004, 30, 721-723.	7.7	0
349	High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. Cancer Treatment Reviews, 2005, 31, 63-67.	7.7	0
350	High-quality evidence in oncology from 1st September to 14th October 2004: a summary. Cancer Treatment Reviews, 2005, 31, 155-157.	7.7	0
351	High-quality evidence in oncology from 14 April to 12 May 2005: A summary. Cancer Treatment Reviews, 2005, 31, 587-589.	7.7	0
352	High-quality evidence in oncology from 19 May to 9 June 2005: A summary. Cancer Treatment Reviews, 2005, 31, 653-656.	7.7	0
353	High-quality evidence in oncology from 16 June to 18 August 2005: A summary. Cancer Treatment Reviews, 2006, 32, 59-64.	7.7	0
354	High-quality evidence in oncology from 25 August to 27 October 2005: A summary. Cancer Treatment Reviews, 2006, 32, 149-155.	7.7	0
355	High-quality evidence in oncology from 3 November to 24 November, 2005: A summary. Cancer Treatment Reviews, 2006, 32, 239-241.	7.7	0
356	High-quality evidence in oncology from 1 December to 22 December 2005: a summary. Cancer Treatment Reviews, 2006, 32, 402-405.	7.7	0
357	Evidence profiles for colo-rectal cancer: Benefit/harms data based on the totality of randomized evidence. Cancer Treatment Reviews, 2006, 32, 577-580.	7.7	0
358	Evidence profiles for lung cancer: Benefit/harms data based on the totality of randomized evidence. Cancer Treatment Reviews, 2006, 32, 652-655.	7.7	0
359	Risk Prediction Versus Diagnosis: Preserving Clinical Nuance in a Binary World. Annals of Internal Medicine, 2009, 150, 223.	3.9	0
360	SYSTEMATIC REVIEWS FOR PROSTATE CANCER: OVERWHELMING TASK FOR CLINICIANS. Journal of Urology, 2009, 181, 6-6.	0.4	0

#	Article	IF	Citations
361	67 ADVANCING COMPARATIVE EFFECTIVENESS RESEARCH THROUGH NETWORK META-ANALYSIS: INTRAVESICAL THERAPY IN BLADDER CANCER. Journal of Urology, 2012, 187, .	0.4	0
362	Comparison of Mycophenolate Mofetil (MMF) Versus Methotrexate (MTX) for Prevention of Acute Graft-Versus-Host Disease: Results of a Meta-Analysis. Biology of Blood and Marrow Transplantation, 2012, 18, S358-S359.	2.0	0
363	Study Design and the Drug Development Processâ€"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 2023.	7.4	0
364	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. The Cochrane Library, 0, , .	2.8	0
365	Chemoprevention agents for prostate cancer. The Cochrane Library, 0, , .	2.8	0
366	Reply. Hepatology, 2016, 63, 1051-1051.	7.3	0
367	Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age â‰¥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S201-S202.	0.4	0
368	A forgotten Î³ error. Journal of Evaluation in Clinical Practice, 2019, 25, 751-753.	1.8	0
369	Detection of Cytokeratin-19 in Peripheral Blood of Breast Cancer Patients: Results from a Systematic Review/Meta-Analysis.. Blood, 2004, 104, 5314-5314.	1.4	0
370	Quality of Reporting of Harms in the NCI Sponsored Phase III Hematological Malignancies Trials.. Blood, 2005, 106, 292-292.	1.4	0
371	Citation Impact of Breakthrough Interventions for Malignant Blood Disorders.. Blood, 2005, 106, 3115-3115.	1.4	0
372	Relationship of Harvest CD34+ and CD3+ Counts To Chronic Graft-Versus-Host Disease (cGVHD), Relapse and Survival Following Sibling Allogeneic Stem Cell Transplant.. Blood, 2005, 106, 1820-1820.	1.4	0
373	Role of High-Dose Chemotherapy with Autologous Haematopoetic Stem Cell Transplantation for Relapsed or Refractory Hodgkinâ€™s Disease.. Blood, 2006, 108, 5432-5432.	1.4	0
374	Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.. Blood, 2007, 110, 3340-3340.	1.4	0
375	Treatment Success in Cancer.. Blood, 2007, 110, 631-631.	1.4	0
376	Thalidomide Versus Bortezomib-Based Regimens for Relapsed Myeloma: Meta-Analysis and Indirect Meta-Analysis. Blood, 2008, 112, 2362-2362.	1.4	0
377	Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes. Blood, 2010, 116, 3995-3995.	1.4	0
378	Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis. Blood, 2010, 116, 3511-3511.	1.4	0

#	Article	IF	Citations
379	Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials. Blood, 2011, 118, 673-673.	1.4	0
380	Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. Blood, 2011, 118, 508-508.	1.4	0
381	External Validation of Prognostic Models in Terminally Ill Patients,. Blood, 2011, 118, 4186-4186.	1.4	0
382	Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis. Blood, 2012, 120, 236-236.	1.4	0
383	Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2012, 120, 4519-4519.	1.4	0
384	Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis. Blood, 2012, 120, 4271-4271.	1.4	0
385	Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM). Blood, 2012, 120, 4239-4239.	1.4	0
386	Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma.. Blood, 2012, 120, 2975-2975.	1.4	0
387	Evaluation of spot urine protein to creatinine ratio and 24-hour urine protein quantification for proteinuria in patients with plasma cell dyscrasia.. Journal of Clinical Oncology, 2013, 31, e19516-e19516.	1.6	0
388	Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. Blood, 2013, 122, 1945-1945.	1.4	0
389	A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia. Blood, 2013, 122, 3155-3155.	1.4	0
390	Meta-Analysis Evaluating Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation As Front-Line Consolidation in Chronic Lymphocytic Leukemia: Results Do Not Justify This Treatment Approach. Blood, 2014, 124, 1306-1306.	1.4	0
391	Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients. Blood, 2016, 128, 3998-3998.	1.4	0
392	Improving Hospice Referral: Application of Regret-Based Decision Modeling at End-of-Life Care. Blood, 2016, 128, 535-535.	1.4	0
393	Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma. Blood, 2018, 132, 5638-5638.	1.4	0
394	How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations. Blood, 2018, 132, 4707-4707.	1.4	0
395	The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines. Blood, 2018, 132, 2237-2237.	1.4	0
396	The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. , 0, , 402-411.		0

#	Article	IF	Citations
397	A clinical score identified cancer patients with febrile neutropenia at low risk for complications. ACP Journal Club, 2001, 134, 76.	0.1	0